Dong-A ST (170900 KS/Buy)Pipeline Progress Needed
We lower our target price for Dong-A ST to W50,000 (vs. the previous adjusted target price of W64,854, which reflects the share count change...
92 Views
Primer: Dong A St (170900 KS) - Aug 2026
Dong-A ST is navigating a challenging transition, with strong top-line revenue growth driven by its ethical pharmaceuticals (ETC) and overseas...
112 Views
Dong-A ST (170900 KS/Buy)Top-Line Growth Continues, but Margin Improvement Remains Limited
Imuldosa (Stelara biosimilar), previously treated as a pipeline asset and valued at W111.1bn, has now been incorporated into operating value...
117 Views
APAC Healthcare Weekly (June 14) – Wuxi AppTec, Remegen, CSPC Pharma, Takeda, SK Bioscience Alteogen
US DoD designated Wuxi AppTec as a “Chinese military company.” Takeda’s zasocitinib tops BMS’ Sotyktu in head-to-head trial. Alteogen secured...
132 Views
APAC Healthcare Weekly (May 31) – Innovent Biologics, Junshi Bio, Henlius Bio, Olympus, GC Bio
Innovent stuck $10.5B outlicensing deal with Pfizer. Olympus will acquire BioProtect. Eli Lilly is acquiring GC Bio’s US affiliate. Dong-A’s...
159 Views